Expert Insights on GCT Cold Chain Logistics
-
Upgrading The Vial/Vein-To-Vein Process With Enterprise-Level Digital Infrastructure
1/21/2025
The cell and gene therapy's value chain has come to be known as the vein-to-vein/vial-to-vein process. Enterprise-level digital infrastructure can address the sector's challenges in a variety of ways.
-
Survey Findings: How Are IDMP Readiness Efforts Progressing?
12/13/2024
ISO Identification of Medicinal Products (IDMP) standards were designed to harmonize the way the life sciences industry records and manages data about its products. Companies’ state of readiness to implement and harness IDMP still varies.
-
The 4 Technologies Poised To Transform The Pharmaceutical Supply Chain In 2025 And Beyond
12/2/2024
These key technological advancements will significantly impact the pharma/biotech supply chain in 2025 and beyond. If you aren't implementing any of them yet, you may want to rethink your plans.
-
Solving The Leukopak Supply Chain Issue With Cryopreservation
11/25/2024
Allogeneic cell therapy developers report an alarming number of starting materials arrive at the wrong temperatures, late, or fail to arrive altogether.
-
Is The BIOSECURE Act The First Real Step Toward Reshoring?
11/22/2024
The U.S. pharma industry has relied heavily on China and India to produce regulatory starting materials and APIs. The BIOSECURE Act has now emerged. Is this the first real step toward reshoring?
-
Sourcing Plasmid DNA From CDMOs Got More Challenging — Here's Why
11/19/2024
The demand for plasmid DNA products is intrinsically linked to unique market conditions and funding environments. Here's what's driving them.
-
3 Focus Areas To Transition From Clinical To Commercial Readiness
11/12/2024
Transitioning from clinical-stage operations to commercial readiness is a multifaceted process. Establish compliant and robust distribution systems by focusing on these three areas.
-
A Comprehensive Guide For Supplier Quality Agreements
10/29/2024
This overview of SQAs includes a handy matrix template, which is useful for determining who is responsible for managing specific responsibilities.
-
Cell & Gene Therapies: Avoid This Common Pitfall In Supply Chain Planning
10/24/2024
BioPhorum members propose a Design for Supply model for cell and gene therapy supply chain planning. Don't let it take a backseat until the later stages of the product life cycle.
-
What's Next After FDA's DSCSA Extension?
10/18/2024
Facing growing pressure from industry and Congress, FDA extended its enforcement deadline yet again, which has important implications for manufacturers.